Loughborough University
Leicestershire, UK
LE11 3TU
+44 (0)1509 263171
Loughborough University

Loughborough University Institutional Repository

Please use this identifier to cite or link to this item: https://dspace.lboro.ac.uk/2134/25986

Title: Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products
Authors: Hourd, Paul C.
Chandra, Amit
Alvey, David
Ginty, Patrick J.
McCall, Mark J.S.
Ratcliffe, Elizabeth
Rayment, Erin
Williams, David J.
Keywords: ATMP
Autologous
Automation
Cell therapy
GMP
Manufacturing
Qualification
Regulation
Validation
Issue Date: 2014
Publisher: © Future Medicine
Citation: HOURD, P.C. ...et al., 2014. Qualification of academic facilities for small-scale automated manufacture of autologous cell-based products. Regenerative Medicine, 9(6), pp. 799-815.
Abstract: Academic centres, hospitals and small companies, as typical development settings for UK regenerative medicine assets, are significant contributors to the development of autologous cell-based therapies. Often lacking the appropriate funding, quality assurance heritage or specialist regulatory expertise, qualifying aseptic cell processing facilities for Good Manufacturing Practice (GMP) compliance is a significant challenge. The qualification of a new Cell Therapy Manufacturing Facility (CTMF) with automated processing capability, the first of its kind in a UK academic setting, provides a unique demonstrator for the qualification of small-scale, automated facilities for GMP compliant manufacture of autologous cell-based products in these settings. This paper shares our experiences in qualifying the CTMF, focussing on our approach to streamlining the qualification effort, the challenges, project delays and inefficiencies we encountered and the subsequent lessons learned.
Description: This paper was accepted for publication in the journal Regenerative Medicine and the definitive published version is available at http://dx.doi.org/10.2217/rme.14.47
Sponsor: Funding and support of the EPSRC is acknowledged. Initial funding was secured from its Innovative Manufacturing and the Life Sciences Interface Programmes both for the remedi Grand Challenge and its successor; the EPSRC Centre for Innovative Manufacturing in Regenerative Medicine. The construction of the CTMF was funded by Loughborough University and the former East Midlands Development Agency (emda). Support for the validation of the CTMF was provided by the Technology Strategy Board (TSB) and the Knowledge Transfer Account (KTA) of Loughborough University, funded by EPSRC.
Version: Accepted for publication
DOI: 10.2217/rme.14.47
URI: https://dspace.lboro.ac.uk/2134/25986
Publisher Link: http://dx.doi.org/10.2217/rme.14.47
ISSN: 1746-0751
Appears in Collections:Published Articles (Mechanical, Electrical and Manufacturing Engineering)
Published Articles (Chemical Engineering)

Files associated with this item:

File Description SizeFormat
Ratcliffe_RM+Submission_Revised+version+3+6_with+Figs.pdfAccepted version666.69 kBAdobe PDFView/Open

 

SFX Query

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.